Skip to content
Inciteful Med

Diagnosis and Understanding Your Reports

Last updated:

The gold standard for diagnosing Oculopharyngeal Muscular Dystrophy (OPMD) is genetic testing of the PABPN1 gene. If your test shows a GCN repeat expansion, the diagnosis is confirmed. Muscle biopsies and EMGs are only needed if genetic results are unclear.

Key Takeaways

  • • Genetic testing of the PABPN1 gene is the definitive, gold-standard method for diagnosing OPMD.
  • • Your genetic report may list a GCG repeat count or total alanine count, which confirms the diagnosis if the numbers fall within the OPMD range.
  • • If genetic tests are inconclusive, a muscle biopsy looking for PABPN1-positive intranuclear inclusions (protein clumps) can confirm the diagnosis.
  • • An EMG test for OPMD typically shows a myopathic pattern, indicating the issue originates in the muscles rather than the nerves.

Navigating the diagnostic process for Oculopharyngeal Muscular Dystrophy (OPMD) can feel overwhelming. Understanding the terminology in your clinical and lab reports is a powerful way to engage with your care team and gain clarity about your condition [1][2].

The Path to Diagnosis

A diagnosis of OPMD is typically reached through a combination of a physical exam, a review of your family history, and definitive laboratory testing [3][2]. Because the symptoms—drooping eyelids (ptosis) and swallowing difficulty (dysphagia)—can resemble other conditions, confirming the diagnosis with specific tests is essential [2][4].

The Gold Standard: Genetic Testing

The most definitive way to confirm OPMD is through genetic testing of the PABPN1 gene [2][4].

  • What to look for: Your report should mention an “alanine-encoding trinucleotide repeat expansion” or a “GCN repeat expansion” [5][6].
  • The Numbers: Laboratories report these results in different ways [5]. Your report might list the GCG repeat count (where 6 is normal, and 8 to 13 indicates OPMD) or the total alanine count (where 10 is normal, and 12 to 18 indicates OPMD) [5][7]. Knowing your specific number can help your doctor understand the likely progression of your symptoms [3][8]. See The Biology of OPMD for more details.

Muscle Biopsy: Seeing the Evidence

While genetic testing is often the first step, a muscle biopsy may be performed if the genetic results are unclear or if your doctor needs to rule out other muscle diseases [9].

  • PABPN1-Positive Intranuclear Inclusions (INIs): This is the hallmark of OPMD [10]. These are tiny “clumps” of protein found inside the nucleus (the control center) of your muscle cells [11][12]. Finding these is nearly 100% sensitive for OPMD [9].
  • Rimmed Vacuoles: These are small, clear spaces or “holes” seen in the muscle fibers under a microscope [13][14]. While they are common in OPMD, they can also be found in other types of muscular dystrophy, so they are always interpreted alongside the protein “clumps” [13][15].

Electromyography (EMG): Measuring Muscle Activity

An EMG test involves placing small needles into muscles to record their electrical activity [16].

  • The “Myopathic Pattern”: In OPMD, the EMG typically shows what doctors call a “myopathic pattern” [16][17]. This means the electrical signals are shorter or smaller than normal, indicating that the problem is within the muscle itself rather than the nerves [16][18].

Understanding Your Diagnostic Pathway

To ensure your diagnosis is fully confirmed, your medical team will look for specific evidence. Note: A positive genetic test is definitive on its own; if your genetic test is positive, you do not need an EMG or a muscle biopsy for a “complete” diagnosis [2].

  1. Clinical History: Documentation of late-onset ptosis, dysphagia, and/or proximal limb weakness [3][5].
  2. Definitive Genetic Confirmation: A report specifying the expansion in the PABPN1 gene [5][6].
  3. Alternative Testing (Only if genetics are unclear): If a biopsy was necessary, the report will mention PABPN1-positive intranuclear inclusions (clumps) and potentially rimmed vacuoles [9][13]. If an EMG was performed, it will note a myopathic pattern [16][17].
  4. Family History: A record of any parents, siblings, or children with similar symptoms [2][5].

Frequently Asked Questions

How is Oculopharyngeal Muscular Dystrophy (OPMD) definitively diagnosed?
The gold standard for diagnosing OPMD is genetic testing of the PABPN1 gene. If this blood test shows a specific repeat expansion, the diagnosis is confirmed and you typically will not need a muscle biopsy or EMG.
What does a positive PABPN1 genetic test mean?
A positive result means you have the genetic mutation responsible for OPMD. Your report will usually list a GCG repeat count (typically 8 to 13) or a total alanine count (typically 12 to 18), which helps your doctor understand your specific condition.
What are PABPN1-positive intranuclear inclusions on a muscle biopsy?
Intranuclear inclusions are tiny clumps of protein found inside the nucleus of muscle cells. Finding these clumps during a muscle biopsy is a hallmark sign of OPMD and is used to confirm the condition if genetic testing is unclear.
Why might my doctor order an EMG for OPMD?
An electromyography (EMG) test measures the electrical activity of your muscles. In OPMD, it typically shows a myopathic pattern, which tells your doctor that your weakness is caused by a problem within the muscles themselves, rather than your nerves.
What do rimmed vacuoles mean on my pathology report?
Rimmed vacuoles are small, clear spaces or holes seen in muscle fibers under a microscope. While they are common in OPMD, they can also appear in other muscle diseases, so pathologists always interpret them alongside other diagnostic clues.

Questions for Your Doctor

  • • Does my genetic report specify the exact number of repeats, and what does this mean for my prognosis?
  • • If my genetic testing was inconclusive, should we consider more specialized sequencing or a muscle biopsy to confirm the diagnosis?
  • • How do the 'myopathic' findings on my EMG correlate with the symptoms I am experiencing in my throat and legs?
  • • Can you explain the significance of the 'rimmed vacuoles' mentioned in my pathology report?
  • • Are the PABPN1-positive inclusions found in my muscle biopsy considered a definitive marker for OPMD in my case?

Questions for You

  • • Do I have a copy of my genetic test results and my muscle biopsy report (if one was performed) for my own records?
  • • Have I shared my diagnosis and genetic results with my family members, since OPMD is usually an inherited condition?
  • • When I read my reports, are there any terms or findings that I don't understand and need to ask my doctor about?
  • • Am I noticing symptoms that match the 'core triad' of OPMD (drooping eyelids, swallowing trouble, and leg weakness)?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Patient-reported disease burden in oculopharyngeal muscular dystrophy.

    Kurtz NS, Cote C, Heatwole C, et al.

    Muscle & nerve 2019; (60(6)):724-731 doi:10.1002/mus.26712.

    PMID: 31531865
  2. 2

    Oculopharyngeal Muscular Dystrophy, an Often Misdiagnosed Neuromuscular Disorder: A Southern California Experience.

    Goyal NA, Mozaffar T, Chui LA

    Journal of clinical neuromuscular disease 2019; (21(2)):61-68 doi:10.1097/CND.0000000000000271.

    PMID: 31743248
  3. 3

    Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy.

    Richard P, Trollet C, Stojkovic T, et al.

    Neurology 2017; (88(4)):359-365 doi:10.1212/WNL.0000000000003554.

    PMID: 28011929
  4. 4

    Choked: A Case Report of Oculopharyngeal Muscular Dystrophy Mimicking Hypothyroidism From the Philippines.

    Infante JM, Nepomuceno BL

    Cureus 2023; (15(6)):e41025 doi:10.7759/cureus.41025.

    PMID: 37519616
  5. 5

    Recent Progress in Oculopharyngeal Muscular Dystrophy.

    Yamashita S

    Journal of clinical medicine 2021; (10(7)) doi:10.3390/jcm10071375.

    PMID: 33805441
  6. 6

    Diagnostics of short tandem repeat expansion variants using massively parallel sequencing and componential tools.

    de Leeuw RH, Garnier D, Kroon RMJM, et al.

    European journal of human genetics : EJHG 2019; (27(3)):400-407 doi:10.1038/s41431-018-0302-4.

    PMID: 30455479
  7. 7

    The small compound Icerguastat reduces muscle defects in oculopharyngeal muscular dystrophy through the PERK pathway of the unfolded protein response.

    Naït-Saïdi R, Chartier A, Abgueguen E, et al.

    Open biology 2023; (13(4)):230008 doi:10.1098/rsob.230008.

    PMID: 37042114
  8. 8

    Insights into the heterogeneity of oculopharyngeal muscular dystrophy.

    Kekou K, Papadopoulos C, Svingou M, et al.

    Neurogenetics 2025; (26(1)):68 doi:10.1007/s10048-025-00849-0.

    PMID: 40991068
  9. 9

    Value of insoluble PABPN1 accumulation in the diagnosis of oculopharyngeal muscular dystrophy.

    Galimberti V, Tironi R, Lerario A, et al.

    European journal of neurology 2020; (27(4)):709-715 doi:10.1111/ene.14131.

    PMID: 31769567
  10. 10

    PABPN1 gene therapy for oculopharyngeal muscular dystrophy.

    Malerba A, Klein P, Bachtarzi H, et al.

    Nature communications 2017; (8()):14848 doi:10.1038/ncomms14848.

    PMID: 28361972
  11. 11

    Nuclear poly(A)-binding protein aggregates misplace a pre-mRNA outside of SC35 speckle causing its abnormal splicing.

    Klein P, Oloko M, Roth F, et al.

    Nucleic acids research 2016; (44(22)):10929-10945 doi:10.1093/nar/gkw703.

    PMID: 27507886
  12. 12

    [Nuclear aggregates in oculopharyngeal muscular dystrophy].

    Boulinguiez A, Roth F, Mouigni HR, et al.

    Medecine sciences : M/S 2022; (38 Hors série n° 1()):13-16 doi:10.1051/medsci/2022175.

    PMID: 36649629
  13. 13

    The phenotypic and genotypic features of Chinese patients with oculopharyngeal muscular dystrophy.

    Lin F, Yang K, Lin MT, et al.

    Annals of clinical and translational neurology 2023; (10(3)):426-439 doi:10.1002/acn3.51733.

    PMID: 36691350
  14. 14

    Recurrent Pneumonia in a Patient With Oculopharyngeal Muscular Dystrophy (OPMD) due to GCN Expansion in the PABPN1 Gene: A Diagnostic Challenge.

    Mañana Valdés C, Arias Guillén M, Moris de la Tassa G

    Open respiratory archives 2026; (8(2)):100580 doi:10.1016/j.opresp.2026.100580.

    PMID: 41676387
  15. 15

    Nuclear inclusions mimicking poly(A)-binding protein nuclear 1 inclusions in a case of inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia with a novel mutation in the valosin-containing protein gene.

    Matsubara S, Shimizu T, Komori T, et al.

    Neuromuscular disorders : NMD 2016; (26(7)):436-40.

    PMID: 27209344
  16. 16

    A Japanese case of oculopharyngeal muscular dystrophy (OPMD) with PABPN1 c.35G > C; p.Gly12Ala point mutation.

    Nishii YS, Noto YI, Yasuda R, et al.

    BMC neurology 2021; (21(1)):265 doi:10.1186/s12883-021-02300-x.

    PMID: 34225694
  17. 17

    Dropped-head in recessive oculopharyngeal muscular dystrophy.

    Garibaldi M, Pennisi EM, Bruttini M, et al.

    Neuromuscular disorders : NMD 2015; (25(11)):869-72.

    PMID: 26494409
  18. 18

    A South African family with oculopharyngeal muscular dystrophy: Clinical and molecular genetic characteristics.

    Schutte CM, Dorfling CM, van Coller R, et al.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 2015; (105(7)):540-3 doi:10.7196/SAMJnew.7880.

    PMID: 26428746

This page is for informational purposes only and does not replace professional medical advice. Always consult your neurologist or genetic counselor for help interpreting your specific OPMD lab and pathology reports.

Stay up to date

Get notified when new research about Oculopharyngeal muscular dystrophy is published.

No spam. Unsubscribe anytime.